Annual General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG / Annual General Meeting of Shareholders of Basilea Pharmaceutica Ltd. processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, March 30, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN)
shareholders approve all Board of Directors' proposals at the Annual General
Meeting.
Today, the shareholders of Basilea approved the annual report, the financial
statements and consolidated financial statements for the business year 2009, as
well as discharge of the members of the Board of Directors and of Management.
Shareholders also approved to carry forward retained earnings for Basilea
Pharmaceutica Ltd.
Mr. Werner Henrich and Mr. Claude Schreiner were both re-elected as members of
the Board of Directors for a term of three years.
Shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory Auditors
for the stand-alone and consolidated financial statements for the business year
2010.
Shareholders approved an amendment of Article 3a paragraph 1 of the Articles of
Incorporation related to the increase of conditional share capital. Further, a
change of Article 4 of the Articles of Incorporation, reflecting the new federal
law on intermediated securities, was approved by shareholders.
The Board of Directors confirmed Mr. Werner Henrich as Chairman of the Board of
Directors and Mr. Steven D. Skolsky as Vice-Chairman.
The Annual General Meeting for the financial year 2009 was attended by
shareholders representing 39.4% of the total share capital of the company.
In his presentation to shareholders, Dr. Anthony Man, CEO Basilea Pharmaceutica
Ltd., commented: "Basilea experienced successes as well as challenges in 2009.
We are very proud of the successful commercialization of Toctino in first key
markets reflecting the innovation and pharmacoeconomic value of Toctino.
However, the delays following the review of the market applications for
ceftobiprole were setbacks." Dr. Anthony Man added: "In 2010, we aim to create
shareholder value by further expanding patient access to Toctino and bringing
forward isavuconazole with Astellas to achieve its full potential as a novel
therapeutic option for life-threatening fungal infections. We also focus on an
efficient transfer of ceftobiprole back to Basilea and we anticipate moving two
promising compounds from our research pipeline into clinical development."
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on
the SIX Swiss Exchange (SIX:BSLN). Basilea's integrated research and development
operations are currently focused on new antibacterial, antifungal and oncology
agents to fight drug resistance and on the development of dermatology drugs.
Basilea's products are targeted to satisfy high medical and patient needs in the
hospital and specialty care setting.
The company owns a diversified portfolio including two commercialized drugs
(Toctino®, ZEFTERA(TM)/ Zevtera(TM)) and one investigational drug
(isavuconazole) in phase III clinical development. Basilea has entered into a
license, co-development and co-promotion agreement with Astellas Pharma Inc. for
isavuconazole for the treatment of life-threatening invasive fungal infections
on a worldwide basis, including an option for Japan. Toctino® (alitretinoin) is
marketed in Denmark, France, Germany, Switzerland and the United Kingdom. It is
approved in eight additional European countries as well as in Canada and has
been recommended for approval in 14 European countries. Furthermore, a phase III
clinical trial on alitretinoin for the treatment of severe chronic hand eczema
is ongoing in the U.S.
Ceftobiprole is marketed in Canada under the brand name ZEFTERA(TM) and in
Switzerland under Zevtera(TM). Basilea has set up commercial organizations in
Canada, France, Germany, the Nordics, Switzerland and the United Kingdom, while
it is building sales and marketing organizations in other countries to
commercialize alitretinoin.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
future events or otherwise.
For further information, please contact:
+----------------------------------------+-------------------------------------+
|Media Relations |Investor Relations |
+----------------------------------------+-------------------------------------+
|Adesh Kaul |Barbara Zink, Ph.D., MBA |
|Head Public Relations & |Head Corporate Development |
|Corporate Communications |+41 61 606 1233 |
|+41 61 606 1460 | |
|media_relations(at)basilea.com |investor_relations(at)basilea.com |
|
+----------------------------------------+-------------------------------------+
This press release can be downloaded from www.basilea.com
The press release can also be downloaded from the following link:
[HUG#1399401]
--- End of Message ---
Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland
WKN: A0B9GA;ISIN: CH0011432447;
Press release (PDF): http://hugin.info/134390/R/1399401/354912.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 30.03.2010 - 11:31 Uhr
Sprache: Deutsch
News-ID 1012230
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Basel
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 239 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Annual General Meeting of Shareholders of Basilea Pharmaceutica Ltd.
"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
